ONX-0914-TFA

Category	Human immunodeficiency Virus (HIV)
Description	ONX-0914 (PR-957) TFA is a selective inhibitor of low-molecular mass polypeptide-7 (LMP7), the chymotrypsin-like subunit of the immunoproteasome. ONX-0914 TFA blocks cytokine production and attenuates progression of experimental arthritis.

Quotation Now

Molecular Weight	694.70
Molecular Formula	C31H41F3N4O9
Boiling Point	878.0±65.0 °C at 760 mmHg
Flash Point	484.8±34.3 °C
Purity	≥98% (HPLC)
Density	1.2±0.1 g/cm3
Solubility	In vitro: 10 mM in DMSO
Appearance	White to off-white (Solid)
Storage	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Index Of Refraction	1.569
In Vitro	ONX-0914 inhibits LMP7-specific antigen presentation. ONX-0914 blocks cytokine productionby mouse splenocytes and blocks T celldifferentiation.
In Vivo	ONX-0914 (2-10 mg/kg; i.v,; on days 4, 6 and 8) meliorates disease in mouse arthritis ONX-0914 (2, 6 and 10 mg per kg body weight on days 25, 27, 29, 31 and 33; i.v.) treatment also induced a rapid therapeutic response in the T and B cell-dependent CIA (collagen-induced arthritis) model.
PSA	149.07000
Target	Proteasome; Bacterial; HIV
Vapor Pressure	0.0±0.3 mmHg at 25°C